Skip to main content
    A

    Anavex Life Sciences Corp (AVXL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.82
    -0.12 (-12.42%)

    Market Cap: $86.53M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Anavex Life Sciences Corp (AVXL) Earnings: Report Dates and Results

    Updated Jul 30, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Anavex Life Sciences (AVXL) is expected to report earnings on Nov 23, 2026. In the quarter ended Jun 30, 2026, Anavex Life Sciences reported EPS of $0.08, above the -$0.08 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    59%(23/39)
    Avg Surprise
    +12.88%
    Streak
    1 Q

    Upcoming Estimates

    Reports Nov 23, 2026 (est.)Period ending Sep 30, 2026
    EPS Consensus-$0.11
    RangeN/A
    3 analysts
    Revenue Consensus
    N/A
    RangeN/A
    3 analysts
    Reports Feb 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.12
    Range-$0.12 - -$0.12
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago-$0.120.0%
    7d ago-$0.120.0%
    Current-$0.12
    Revenue Consensus
    N/A
    RangeN/A
    0 analysts

    Next Report

    AVXL has an expected report date of Nov 23, 2026.

    AVXL Earnings Call

    The latest AVXL earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, AVXL beat 23, missed 10 and matched 6. The widest gap in the table came in the quarter ended Jun 30, 2026, when EPS landed 200.00% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Jun 30, 2026$0.08-$0.08-$0.08 - -$0.08+200.00%BeatN/A12 up, 0 downJul 30, 2026
    Mar 31, 2026-$0.13-$0.07-$0.07 - -$0.07-85.71%MissN/A12 up, 0 downJun 23, 2026
    Dec 31, 2025-$0.06-$0.11-$0.12 - -$0.10+45.45%BeatN/A21 up, 0 downFeb 9, 2026
    Sep 30, 2025-$0.11-$0.14-$0.16 - -$0.13+22.86%BeatN/A31 up, 1 downNov 25, 2025
    Jun 30, 2025-$0.16-$0.14-$0.16 - -$0.13-14.29%MissN/A21 up, 0 downAug 12, 2025
    Mar 31, 2025-$0.13-$0.15-$0.16 - -$0.14+13.33%BeatN/A21 up, 0 downMay 13, 2025
    Dec 31, 2024-$0.14-$0.17-$0.17 - -$0.17+17.65%BeatN/A11 up, 0 downFeb 12, 2025
    Sep 30, 2024-$0.14-$0.17-$0.17 - -$0.17+17.65%BeatN/A21 up, 0 downDec 23, 2024
    Jun 30, 2024-$0.14-$0.18-$0.21 - -$0.12+22.22%BeatN/A30 up, 0 downAug 6, 2024
    Mar 31, 2024-$0.13-$0.13-$0.13 - -$0.090.00%In lineN/A20 up, 0 downMay 9, 2024
    Dec 31, 2023-$0.11-$0.15-$0.15 - -$0.14+26.67%BeatN/A20 up, 0 downFeb 7, 2024
    Sep 30, 2023-$0.12-$0.15-$0.16 - -$0.13+20.00%BeatN/A30 up, 0 downNov 27, 2023
    Jun 30, 2023-$0.14-$0.17-$0.17 - -$0.16+17.65%BeatN/A30 up, 0 downAug 8, 2023
    Mar 31, 2023-$0.17-$0.18-$0.20 - -$0.18+5.56%BeatN/A30 up, 0 downMay 9, 2023
    Dec 31, 2022-$0.17-$0.19-$0.20 - -$0.18+10.53%BeatN/A30 up, 0 downFeb 7, 2023
    Sep 30, 2022-$0.18-$0.16-$0.17 - -$0.15-12.50%MissN/A50 up, 0 downNov 28, 2022
    Jun 30, 2022-$0.16-$0.16N/A0.00%In lineN/AN/A0 up, 0 downAug 9, 2022
    Mar 31, 2022-$0.14-$0.17-$0.18 - -$0.16+17.65%BeatN/A40 up, 0 downMay 10, 2022
    Dec 31, 2021-$0.14-$0.16-$0.16 - -$0.14+12.50%BeatN/A40 up, 0 downFeb 9, 2022
    Sep 30, 2021-$0.15-$0.14-$0.17 - -$0.13-7.14%MissN/A40 up, 0 downNov 24, 2021
    Jun 30, 2021-$0.14-$0.14-$0.15 - -$0.120.00%In lineN/A5N/AAug 12, 2021
    Mar 31, 2021-$0.12-$0.15-$0.15 - -$0.12+20.00%BeatN/A4N/AMay 13, 2021
    Dec 31, 2020-$0.12-$0.12N/A0.00%In lineN/A2N/AFeb 11, 2021
    Sep 30, 2020-$0.10-$0.13-$0.14 - -$0.12+23.08%BeatN/A4N/ADec 28, 2020
    Jun 30, 2020-$0.11-$0.13-$0.14 - -$0.13+15.38%BeatN/A4N/AAug 6, 2020
    Mar 31, 2020-$0.12-$0.16-$0.20 - -$0.13+25.00%BeatN/A4N/AMay 7, 2020
    Dec 31, 2019-$0.12-$0.12-$0.16 - -$0.120.00%In lineN/A2N/AFeb 6, 2020
    Sep 30, 2019-$0.07-$0.15-$0.15 - -$0.15+53.33%BeatN/A2N/ADec 16, 2019
    Jun 30, 2019-$0.14-$0.17-$0.18 - -$0.16+17.65%BeatN/A2N/AAug 7, 2019
    Mar 31, 2019-$0.17-$0.14-$0.14 - -$0.14-21.43%MissN/A1N/AMay 8, 2019
    Dec 31, 2018-$0.16-$0.13-$0.13 - -$0.13-23.08%MissN/A1N/AFeb 7, 2019
    Sep 30, 2018-$0.13-$0.11N/A-18.18%MissN/AN/AN/ADec 12, 2018
    Jun 30, 2018-$0.06-$0.10-$0.12 - -$0.09+40.00%BeatN/A3N/AAug 9, 2018
    Mar 31, 2018-$0.11-$0.10-$0.10 - -$0.10-10.00%MissN/A2N/AMay 10, 2018
    Dec 31, 2017-$0.09-$0.08N/A-12.50%MissN/AN/AN/AFeb 7, 2018
    Sep 30, 2017-$0.12-$0.10-$0.10 - -$0.10-20.00%MissN/A2N/ADec 11, 2017
    Jun 30, 2017-$0.09-$0.09-$0.09 - -$0.090.00%In lineN/A1N/AAug 7, 2017
    Mar 31, 2017-$0.04-$0.09N/A+55.56%BeatN/AN/AN/AMay 10, 2017
    Dec 31, 2016-$0.08-$0.11N/A+27.27%BeatN/AN/AN/AFeb 7, 2017
    Sep 30, 2016-$0.18N/AN/AN/AN/AN/AN/AN/ADec 12, 2016
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Sep 30, 2026 was -$0.11, after -$0.54 the year before. It was -$0.33 for the year ended Sep 30, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Sep 30, 2026-$0.11N/A
    Sep 30, 2025-$0.54N/A
    Sep 30, 2024-$0.52N/A
    Sep 30, 2023-$0.60N/A
    Sep 30, 2022-$0.62N/A
    Sep 30, 2021-$0.53N/A
    Sep 30, 2020-$0.45N/A
    Sep 30, 2019-$0.54N/A
    Sep 30, 2018-$0.39N/A
    Sep 30, 2017-$0.33N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 3,800 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20263,8176
    2025Q4Dec 31, 20254,2996
    2025Q3Sep 30, 20252,5275
    2025Q2Jun 30, 20252,6605
    2025Q1Mar 31, 20252,5704
    2024Q4Dec 31, 20241,1933
    2024Q2Jun 30, 20242,7765

    2026Q1 Earnings Call

    Opening remarks

    Clint Tomlinson Host Good morning, everyone. And welcome to the Anavex Life Sciences Corp. fiscal 2026 first quarter conference call. My name is Clint Tomlinson. I will be your host for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. During the session, if you would like to ask a question, please use the Q&A box or raise your hand. Please note this conference is being recorded, and the call will be available on Anavex's website at www.anavex.com. With us today is Dr. Christopher Missling, President and Chief Executive Officer, and Sandra Boenisch, Principal Financial Officer. Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the company's filings with the SEC, including, without limitation, the company's forms 10-K and 10-Q, to identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, the need and ability to obtain future capital, and maintenance of intellectual property rights. This conference call discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such products will successfully complete clinical development or gain health authority approval. And with that, I would like to turn the call over to Dr. Missling.

    Christopher Missling CEO Thank you, Clint, and good morning, everyone. Thank you for being with us today to review our first quarter financial results and quarterly business update. As we enter 2026, we continue to progress our innovative clinical pipeline with a particular focus on our lead candidate, oral blarcamesine, in early Alzheimer's disease. Based on our commitment to improving the lives of patients with neurological disorders, we remain excited about the therapeutic potential of oral blarcamesine. We look forward to working with the regulatory agencies in Europe and in the U.S. to advance blarcamesine as a potential new treatment option for patients. We recently announced Anavex's participation as a key industry partner in Access AD, a major new European initiative designed to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer's disease across real-world clinical settings.

    Frequently Asked Questions About AVXL

    When is Anavex Life Sciences's next earnings date?

    Anavex Life Sciences's next earnings report is expected for Nov 23, 2026.

    Did AVXL beat earnings estimates last quarter?

    Yes. Anavex Life Sciences reported EPS of $0.08 for the quarter ended Jun 30, 2026, above the -$0.08 estimate, a 200.00% surprise.

    What EPS do analysts expect from AVXL next quarter?

    The consensus EPS estimate for Anavex Life Sciences for the quarter ended Sep 30, 2026 is -$0.11 from 3 analysts.

    How often does AVXL beat earnings estimates?

    Anavex Life Sciences beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +27.12%.